Medicine and Dentistry
Advance Care Planning
100%
Malignant Neoplasm
99%
Advanced Cancer
82%
Symptomatic Treatment
77%
Systematic Review
63%
Hepatic Encephalopathy
50%
Placebo
42%
Life Expectancy
37%
Meta-Analysis
36%
Care Pathway
36%
Diseases
35%
Clinical Trial
29%
Hazard Ratio
26%
Oncology
25%
Cohort Analysis
25%
Chronic Obstructive Pulmonary Disease
24%
Oncologist
24%
Brain Disease
21%
Quality of Life
20%
Decision Making
20%
Dying
20%
Shared Decision Making
20%
Supportive Care
19%
Butylscopolamine
18%
Cancer Treatment
18%
Observational Study
17%
Clinician
16%
Liver Disease
15%
Patient Referral
15%
Restlessness
14%
Controlled Clinical Trial
13%
Hospital Care
13%
Oral Mucositis
12%
Thrombosis
12%
Prospective Cohort Study
12%
Glutamic Acid
12%
Informed Consent
12%
Visual Evoked Potential
12%
Neuro-Oncology
12%
Reactive Attachment Disorder
12%
Venous Thromboembolism
12%
Clinical Prediction Model
12%
Idiopathic Pulmonary Fibrosis
12%
Anticoagulant Therapy
12%
Volunteer
12%
Randomized Clinical Trial
12%
Hyperammonemia
12%
Evoked Potential
12%
Medical Intervention
12%
Retrospective Cohort Study
12%
Nursing and Health Professions
Malignant Neoplasm
93%
Advance Care Planning
76%
Advanced Cancer
66%
Health Care Personnel
51%
Systematic Review
50%
Self Care
48%
Diseases
46%
Life Expectancy
40%
Quality of Life
33%
Placebo
30%
Oncologist
28%
Cohort Analysis
27%
Hepatic Encephalopathy
24%
Palliative Therapy
23%
Terminal Care
21%
Cancer Center
19%
Shared Decision-Making
19%
Dying
17%
Patient Referral
15%
Fluid Intake
15%
Self-Efficacy
14%
Confidence Interval
13%
Liver Disease
13%
Home Care
13%
Area under the Curve
13%
Psychosocial Disorder
12%
Participatory Action Research
12%
Fibrosing Alveolitis
12%
Obstructive Lung Disease
12%
Volunteer
12%
Prospective Cohort Study
12%
Nurse Practitioner
12%
Health Status
12%
Flumazenil
12%
Deprescribing
12%
Hazard Ratio
12%
Meta Analysis
12%
Transdermal Drug Administration
12%
Duragesic
12%
Hospital Care
12%
Neoplasm
10%
Restlessness
9%
Deprescription
9%
Healthcare System
7%
Logistic Regression Analysis
7%
General Practitioner
7%
Dyspnea
6%
Scopolamine Butyl Bromide
6%
Predictive Value
6%
Patient Decision Making
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
57%
Placebo
36%
Duragesic
36%
Advanced Cancer
34%
Life Expectancy
32%
Pharmacokinetics
29%
Randomized Controlled Trial
27%
Hepatic Encephalopathy
25%
Clinical Trial
24%
Diseases
24%
Scopolamine Butyl Bromide
20%
Dying
20%
Random Effects Model
20%
Comorbidity
16%
Transdermal
15%
Chemotherapy
14%
Neoplasm
13%
Cancer Pain
13%
Controlled Clinical Trial
12%
Observational Study
12%
Chronic Obstructive Lung Disease
12%
Hyperammonemia
12%
Glutamic Acid
12%
Thrombosis
12%
Acute Liver Failure
12%
Medulloblastoma
12%
Oxycodone
12%
Head and Neck Cancer
12%
Liver Disease
12%
Anticoagulant Agent
12%
Venous Thromboembolism
12%
Randomized Clinical Trial
12%
Breakthrough Pain
9%
Xerostomia
8%
Side Effect
8%
Scopolamine
6%
Deterioration
6%
Patient Recruitment
6%
Skin Metastasis
6%
Lung Cancer
6%
Cholinergic Receptor Blocking Agent
6%
Mucosa Inflammation
6%
Serum Albumin
6%
Cognitive Defect
6%
Adverse Event
5%
Cohort Study
5%
Liver Failure
5%